Dirk Lindner

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Vedolizumab clinical decision support tool predicts clinically relevant targets in patients with Crohn's disease.

Vedolizumab clinical decision support tool predicts clinically relevant targets in patients with Crohn's disease.

Journal: Therapeutic advances in gastroenterology

Published: August 04, 2025

Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.

Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.

Journal: Contemporary clinical trials communications

Published: July 30, 2025

Final results from the vedolizumab extended access program multinational study demonstrate long-term treatment persistence and safety.

Final results from the vedolizumab extended access program multinational study demonstrate long-term treatment persistence and safety.

Journal: Therapeutic advances in gastroenterology

Published: July 29, 2025

Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.

Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.

Journal: European journal of gastroenterology & hepatology

Published: February 28, 2024

Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial.

Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 28, 2024

Magnetic Resonance Enterography Assessment of Transmural Healing with Vedolizumab in Moderate to Severe Crohn's Disease: Feasibility in the VERSIFY Phase 3 Clinical Trial.

Magnetic Resonance Enterography Assessment of Transmural Healing with Vedolizumab in Moderate to Severe Crohn's Disease: Feasibility in the VERSIFY Phase 3 Clinical Trial.

Journal: Clinical and experimental gastroenterology

Published: August 18, 2023

Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.

Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.

Journal: Journal of clinical immunology

Published: July 28, 2023

Vedolizumab for the Treatment of Chronic Pouchitis.

Vedolizumab for the Treatment of Chronic Pouchitis.

Journal: The New England journal of medicine

Published: March 29, 2023

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay.

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay.

Journal: Therapeutic drug monitoring

Published: April 11, 2022

Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial.

Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial.

Journal: Diseases of the colon and rectum

Published: December 10, 2021

Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.

Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.

Journal: Alimentary pharmacology & therapeutics

Published: November 12, 2021

Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.

Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.

Journal: Alimentary pharmacology & therapeutics

Published: July 08, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026